ClinicalTrials.gg
Active, not recruitingNCT04644068PETRAUpdated Sep 21, 2026

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

A Phase 1/2 interventional study of AZD5305 and Paclitaxel in Ovarian Cancer, Breast Cancer and Pancreatic Cancer, sponsored by AstraZeneca. Active, not recruiting at 68 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
702
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Ovarian Neoplasms by AstraZeneca — 8 open to participants now, 20 under way, 6 of them phase 3. Ovarian Neoplasms · AstraZeneca.

Enrollment
2nd of 47
702 · median 181
Started
2020
with 5 others
Phase 1/2
8 of 70
3 open now
Primary completion
2027-05
later than 8 of 19 live
Registered
52nd of 70
by date

Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 2nd largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2020, is one of 8 in phase 1/2, reaches primary completion later than 8 of the 19 other live ones, and was the 52nd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

8 of the 70 studies in Ovarian Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Ovarian Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Read the detailed description

This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

03

Conditions studied

  • Ovarian Cancer
  • Breast Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Additional Indications Below for Module 4 and 5
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Gastric Cancer
  • Biliary Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Small Cell Lung Cancer Only in Module 5

Keywords

  • PARP inhibitor
  • Breast Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • AZD5305, T-DXd, Enhertu, Trastuzumab Deruxtecan, Dato-DXd, Datopotamab Deruxtecan, Camizestrant
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 at the time of screening
  • Histological or cytological confirmation of advanced considered to be suitable for study treatment and meeting module specific eligibility criteria..
  • Performance status (ECOG PS: 0-2)
  • ≥ 12 weeks
  • Progressive cancer at the time of study entry
  • Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
  • Adequate organ and marrow function as defined by the protocol.
  • For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.

For Part A:

- Patients may have received up to one with a PARPi-based regimen (either as a treatment or as maintenance)

For Part B:

- Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).

Key Exclusion Criteria:

  • Treatment with any of the following:

    1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
    2. Any agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
    3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
    4. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
  • Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 () strong inhibitors or inducers.
  • Concomitant use of drugs that are known to prolong or shorten and have a known risk of Torsades de Pointes.
  • Receiving continuous at a dose of >10 mg prednisone/day or equivalent for any reason.
  • Major surgery within 4 weeks of the first dose of study treatment.
  • Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
  • Any history of persisting (> 2 weeks) severe pancytopenia due to any cause
  • Spinal cord compression or unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with are excluded.
  • patient with known predisposition to bleeding (e.g., active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).
  • Cardiac conditions as defined by the clinical study protocol
  • Other cardiovascular diseases as defined by any of the following:

    1. Symptomatic heart failure,
    2. uncontrolled hypertension,
    3. hypertensive heart disease with significant left ventricular hypertrophy
    4. acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
    5. cardiomyopathy of any etiology
    6. presence of valvular heart disease
    7. history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (\< 100 beats per minute) are permitted.
    8. subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
    9. , or stroke within 6 months prior to screening
    10. patients with symptomatic hypotension at screening
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
  • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305
  • Known allergy or to investigational product(s) or any of the of the investigational product(s).

Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.

other module-specific criteria may apply

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
702 participants (actual)

Study arms

  • Experimental
    Module 1: AZD5305 Monotherapy

    AZD5305 Monotherapy

    Drug: AZD5305

  • Experimental
    Module 2: AZD5305 + Paclitaxel

    AZD5305 + Paclitaxel

    Drug: AZD5305 · Drug: Paclitaxel

  • Experimental
    Module 3: AZD5305 + Carboplatin with or without Paclitaxel

    AZD5305 + Carboplatin with or without Paclitaxel

    Drug: AZD5305 · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Module 4: AZD5305 + Trastuzumab Deruxtecan

    AZD5305 + T- DXd

    Drug: AZD5305 · Drug: T- Dxd

  • Experimental
    Module 5 AZD5305 + Datopotamab Deruxtecan

    AZD5305 + Dato-DXd

    Drug: AZD5305 · Drug: Dato-DXd

  • Experimental
    Module 6 AZD5305 + Camizestrant

    AZD5305 + Camizestrant

    Drug: AZD5305 · Drug: Camizestrant

Interventions

06

What researchers measure

Primary outcomes

  1. The number of subjects with adverse events/serious adverse events

    Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline

    Time frame: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.

  2. The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.

    A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie, late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators, based on the emerging safety profile.

    Time frame: From first dose of study treatment until the end of Cycle 1.

Secondary outcomes

  1. Best percentage change in target lesion

    Change in target lesion size from baseline, as defined by RECIST 1.1.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  2. Objective Response Rate

    Best response until progression, as defined by RECIST 1.1.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  3. Duration of Response

    Time from first response to progression or death , as defined by RECIST 1.1.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  4. Progression Free Survival

    Time from C1D1 to progression or death, as defined by RECIST 1.1.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  5. Time To Response

    Time from C1D1 to complete or partial response, as defined by RECIST 1.1.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  6. Effects of AZD5305 on pH2AX (Ser139) PD biomarker

    Measure change from baseline in pH2AX

    Time frame: From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)

  7. CA125 response (ovarian cancer)

    at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria.

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  8. Module 1: Area Under Curve (AUC)

    The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  9. Module 1: Maximum plasma concentration of the drug (Cmax)

    The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  10. Module 1: The time taken to reach the maximum concentration (Tmax)

    The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  11. Module 1 and Module 5: Objective Response Rate (prostate cancer)

    Best response until progression, as defined by RECIST 1.1 or PCWG3 (bone)

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  12. Module 1: Radiographic progression free survival (prostate cancer)

    Time from C1D1 to progression or death, as defined by RECIST 1.1 and PCWG3(bone).

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  13. Module 1: Proportion of subjects with ≥ 50% PSA decrease (prostate cancer)

    PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment

    Time frame: From Screening to confirmed progressive disease (approximately 1 year)

  14. Module 1 : To investigate the effect of a high-fat meal on the PK of AZD5305

    Effect on High fat meal on PK parameters of AZD5305.PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without food

    Time frame: Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.

  15. Module 2: Area Under Curve (AUC)

    The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  16. Module 2: Maximum plasma concentration of the drug (Cmax)

    The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  17. Module 2: The time taken to reach the maximum concentration (Tmax)

    The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  18. Module 3: Area Under Curve (AUC)

    The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  19. Module 3: Maximum plasma concentration of the drug (Cmax)

    The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  20. Module 3: The time taken to reach the maximum concentration (Tmax)

    The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  21. Module 4 : Area Under Curve

    The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  22. Module 4: Maximum plasma concentration of the drug (Cmax)

    The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  23. Module 4: The time taken to reach the maximum concentration (Tmax)

    The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  24. Module 4: Anti-Drug Antibody (ADA)

    To investigate the presence of ADAs for T-DXd

    Time frame: Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments

  25. Module 4: To assess the preliminary anti-tumour activity of AZD5305 as monotherapy and in combination with T-DXd.

    Time from C1D1 to progression or death, as defined by RECIST v 1.1 summarised at the 6 month landmark (PFS6)

    Time frame: From screening to approximately 6 months

  26. Module 5: Area Under Curve

    The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  27. Module 5: Maximum plasma concentration of the drug (Cmax)

    The concentration of AZD5305 in plasma will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  28. Module 5: The time taken to reach the maximum concentration (Tmax)

    The concentration of AZD5305 in plasma will be determined (Tmax will be derived).

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  29. Module 5: Anti-Drug Antibody (ADA)

    Presence of ADAs for Dato-DXd

    Time frame: Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.

  30. Module 5: Premilinary anti tumour activity AZD5305 in combination with Dato-DXd

    objective response rate and radiographic progression-free survival using RECIST v1.1. Proportion of patients achieving a ≥ 50% decrease in PSA from baseline to the post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response).

    Time frame: From screening to confirmed progresive disease ( approximately 12 weeks)

  31. Module 6: To characterise the PK of AZD5305 and camizestrant following a single dose and at steady state after multiple dosing, when given in combination.

    Plasma concentrations and PK parameters of AZD5305 and camizestrant after single dose and multiple dose administration, including, but not limited to: AUC, Cmax, Tmax, as data allow

    Time frame: At predefined interval throughout the treatment (approximately 12 weeks)

  32. Module 6: To evaluate the effect of camizestrant on the PK of AZD5305.

    PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without camizestrant.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

  33. Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.

    PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without AZD5305.

    Time frame: At predefined intervals throughout the treatment period (approximately 12 weeks)

07

Study locations

68 sites
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Vancouver, British Columbia V5Z 1K1, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Jining, 272029, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Prague, 15006, Czechia
  • Research Site
    Budapest, 1062, Hungary
  • Research Site
    Budapest, 1082, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Modena, 41125, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Bydgoszcz, 85-796, Poland
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Gdynia, 81-519, Poland
  • Research Site
    Grzepnica, 72-003, Poland
  • Research Site
    Lodz, 90-302, Poland
  • Research Site
    Torun, 87-100, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Moscow, 111123, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 117997, Russia
  • Research Site
    Moscow, 143442, Russia
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Chernivtsі, 58013, Ukraine
  • Research Site
    Ivano-Frankivsk, 76018, Ukraine
  • Research Site
    Kyiv, 03022, Ukraine
  • Research Site
    Uzhhorod, 88000, Ukraine
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Oxford, OX3 7LE, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
08

References and documents

Publications

  • Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkila J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301. PubMed 35929986 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for May 2027, 78 months after the start.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's planned 78 months is above that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 25, 2020
StartActual
Nov 12, 2020
Primary completionEst.
May 28, 2027
CompletionEst.
May 28, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04644068
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Nov 12, 2020
Primary completion
May 28, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Timothy Yap
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD5305

Start the discussion